Neurotech International Ltd. (AU:NTI) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Neurotech International Ltd (ASX: NTI) has made substantial strides in FY2024 with its NTI164 cannabinoid drug therapy, meeting key clinical trial endpoints for several paediatric neurological disorders such as Autism Spectrum Disorder and Rett Syndrome. The company successfully raised $10 million to support its endeavors, including manufacturing and potential registration of NTI164, while also expanding its leadership team with the appointment of a new CEO. Neurotech continues to strengthen its patent portfolio and financial position, promising an exciting year ahead for investors.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.